A Phase II/III Study of TS-152 in Patients with Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to Methotrexate (MTX) Therapy

In patients with active RA who had an inadequate response to MTX, TS-152 30 and 80 mg subcutaneously once every 4 weeks demonstrated significant improvement in ACR20 response rate at week 16 compared with placebo, and the efficacy in the TS-152 groups was comparable at both doses. There was no significant difference in the change from baseline in mTSS at week 24 between TS-152 and placebo groups. TS-152 was well tolerated with no notable safety concerns up to week 52 at both doses.